Uveitis in Vemurafenib-Treated Patients
Original Investigation Research
neous presentations of the inflammation may be observed in this context. The mechanisms that lead to vemurafenibinduced uveitis remain unknown. The continuation of treat-
ARTICLE INFORMATION Submitted for Publication: September 20, 2013; final revision received March 11, 2014; accepted March 12, 2014. Published Online: August 14, 2014. doi:10.1001/jamaophthalmol.2014.3024. Author Contributions: Dr Guedj had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Guedj, Quéant, Lellouch, Gantzer, Brézin. Acquisition, analysis, or interpretation of data: Guedj, Quéant, Funck-Brentano, Kramkimel, Monnet, Longvert, Brézin. Drafting of the manuscript: Guedj, Quéant, Lellouch, Gantzer, Brézin. Critical revision of the manuscript for important intellectual content: Quéant, Funck-Brentano, Kramkimel, Monnet, Longvert, Brézin. Statistical analysis: Guedj.
ment or its discontinuation require careful balancing between the expected benefits of treatment vs its ocular adverse effects.
Administrative, technical, or material support: Guedj, Funck-Brentano. Study supervision: Guedj, Quéant, Funck-Brentano, Monnet, Gantzer, Brézin.
IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol. 2008;26(4):527-534.
REFERENCES
5. Arimone Y, Bidault I, Dutertre JP, et al; Cercle de Reflexion sur l’Imputabilite. Update of the French drug reaction assessment method [in French]. Therapie. 2011;66(6):517-525.
1. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363(9):809-819.
6. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356(9237):1255-1259.
2. Chapman PB, Hauschild A,Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364(26):2507-2516.
7. da Rocha Dias S, Salmonson T, van Zwieten-Boot B, et al. The European Medicines Agency review of vemurafenib (Zelboraf®) for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use. Eur J Cancer. 2013;49(7):1654-1661.
Conflict of Interest Disclosures: None reported.
3. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366(8):707 -714. 4. Korn EL, Liu PY, Lee SJ, et al. Meta-analysis of phase II cooperative group trials in metastatic stage
OPHTHALMIC IMAGES
Ointment in the Anterior Chamber Sandro Sbordone, MD; Alfonso Savastano, MD; Vito Romano, MD
Postoperative hypotony presumably allowed ointment to gain entrance into the anterior and posterior chambers (arrowheads) as photographed 4 weeks after phacoemulsification.
jamaophthalmology.com
JAMA Ophthalmology December 2014 Volume 132, Number 12
Copyright 2014 American Medical Association. All rights reserved.
Downloaded From: http://archopht.jamanetwork.com/ by a Karolinska Institutet University Library User on 06/02/2015
1425
Original Investigation Research
neous presentations of the inflammation may be observed in this context. The mechanisms that lead to vemurafenibinduced uveitis remain unknown. The continuation of treat-
ARTICLE INFORMATION Submitted for Publication: September 20, 2013; final revision received March 11, 2014; accepted March 12, 2014. Published Online: August 14, 2014. doi:10.1001/jamaophthalmol.2014.3024. Author Contributions: Dr Guedj had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Guedj, Quéant, Lellouch, Gantzer, Brézin. Acquisition, analysis, or interpretation of data: Guedj, Quéant, Funck-Brentano, Kramkimel, Monnet, Longvert, Brézin. Drafting of the manuscript: Guedj, Quéant, Lellouch, Gantzer, Brézin. Critical revision of the manuscript for important intellectual content: Quéant, Funck-Brentano, Kramkimel, Monnet, Longvert, Brézin. Statistical analysis: Guedj.
ment or its discontinuation require careful balancing between the expected benefits of treatment vs its ocular adverse effects.
Administrative, technical, or material support: Guedj, Funck-Brentano. Study supervision: Guedj, Quéant, Funck-Brentano, Monnet, Gantzer, Brézin.
IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol. 2008;26(4):527-534.
REFERENCES
5. Arimone Y, Bidault I, Dutertre JP, et al; Cercle de Reflexion sur l’Imputabilite. Update of the French drug reaction assessment method [in French]. Therapie. 2011;66(6):517-525.
1. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363(9):809-819.
6. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356(9237):1255-1259.
2. Chapman PB, Hauschild A,Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364(26):2507-2516.
7. da Rocha Dias S, Salmonson T, van Zwieten-Boot B, et al. The European Medicines Agency review of vemurafenib (Zelboraf®) for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use. Eur J Cancer. 2013;49(7):1654-1661.
Conflict of Interest Disclosures: None reported.
3. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366(8):707 -714. 4. Korn EL, Liu PY, Lee SJ, et al. Meta-analysis of phase II cooperative group trials in metastatic stage
OPHTHALMIC IMAGES
Ointment in the Anterior Chamber Sandro Sbordone, MD; Alfonso Savastano, MD; Vito Romano, MD
Postoperative hypotony presumably allowed ointment to gain entrance into the anterior and posterior chambers (arrowheads) as photographed 4 weeks after phacoemulsification.
jamaophthalmology.com
JAMA Ophthalmology December 2014 Volume 132, Number 12
Copyright 2014 American Medical Association. All rights reserved.
Downloaded From: http://archopht.jamanetwork.com/ by a Karolinska Institutet University Library User on 06/02/2015
1425
